What is the Concord Biotech Ltd share price today?

The share price of NSE:CONCORDBIO-EQ on 07 Sep 2026 (as of 10:59:04 IST) is ₹1437.40.

What is the NSE:CONCORDBIO-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:CONCORDBIO-EQ 52 week high low range shows a high of ₹1704.00 and a low of ₹987.00.

What is the Concord Biotech Ltd market cap?

As on 07 Sep 2026, Concord Biotech Ltd market cap is ₹14800.60 Cr.

What is the shareholding pattern of Concord Biotech Ltd Stock?

The shareholding pattern of Concord Biotech Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 44.08% Foreign Institutional Investors (FII): 7.53% Domestic Institutional Investors (DII): 4.97% Mutual Funds: 4.40% Retail & Others: 39.02% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Concord Biotech Ltd?

The Price-to-Earnings (PE) ratio of Concord Biotech Ltd is 53.75, and the Price-to-Book (PB) ratio is 5.27, as on 07 Sep 2026.

Concord Biotech Share Price

1480.00-80.30 (-5.15%)

-8.89% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-5.15%

1 Week

-0.96%

1 Month

-4.39%

3 Month

+15.08%

6 Month

+45.84%

YTD

+9.99%

1 Year

-8.89%

5 Year

10 Year

Max

+64.44%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1472.70

1411.60

1238.00

987.00

High

1548.50

1592.00

1615.00

1667.60

About

Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

CONCORDBIONSE

LTP

1W Low

1W High

Market cap (₹)

1851+13.7 (0.75%)

1832.20

1891.50

4,47,476Cr

9630+255 (2.72%)

9312.50

9740

2,54,764Cr

4902+62 (1.28%)

4848.50

5010

1,89,423Cr

1183.6+23.6 (2.03%)

1152.10

1190.60

1,16,658Cr

1399+4.5 (0.32%)

1364.50

1419

1,11,484Cr

2025.2+71.2 (3.64%)

1963.80

2055.30

1,09,943Cr

2480.5+179.8 (7.82%)

2303

2504.30

1,01,712Cr

1202.6+17.6 (1.49%)

1185

1222

1,01,005Cr

1720-14 (-0.81%)

1689.30

1740

99,253Cr

2090.3+7.3 (0.35%)

2080

2135

96,031Cr

1480.3-14.1 (-0.94%)

1472.70

1592

16,312Cr

Concord Biotech Share Price

1480.00-80.30 (-5.15%)

-8.89% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years11%

3 years7%

Last year-12%

Compounded Profit Growth

10 years-

5 years2%

3 years3%

Last year-30%

Stock Price CAGR

10 years-

5 years-

3 years17%

1 year-4%

Return on Equity

10 years20%

5 years19%

3 years19%

Last year14%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	11%	7%	-12%
-	2%	3%	-30%
-	-	17%	-4%
20%	19%	19%	14%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

CONCORDBIO

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,851	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,630	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,902	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,183.6	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,399	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,025.2	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,480.5	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,202.6	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,720	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,090.3	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
1,480	₹16312 Cr	59.23	5.59	33.47	₹261 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
₹257 Cr	₹326 Cr	₹278 Cr	₹247 Cr	₹204 Cr	₹430 Cr	₹244 Cr	₹310 Cr	₹216 Cr	₹319 Cr	₹241 Cr	₹262 Cr	₹195 Cr	₹273 Cr	₹241 Cr	₹159 Cr	₹181 Cr
₹13 Cr	₹15 Cr	₹10 Cr	₹13 Cr	₹14 Cr	₹9 Cr	₹15 Cr	₹10 Cr	₹10 Cr	₹11 Cr	₹8 Cr	₹8 Cr	₹7 Cr	₹12 Cr	₹9 Cr	₹6 Cr	₹8 Cr
₹270 Cr	₹341 Cr	₹288 Cr	₹260 Cr	₹218 Cr	₹439 Cr	₹259 Cr	₹320 Cr	₹226 Cr	₹330 Cr	₹249 Cr	₹270 Cr	₹201 Cr	₹285 Cr	₹250 Cr	₹165 Cr	₹189 Cr
₹193 Cr	₹227 Cr	₹198 Cr	₹177 Cr	₹160 Cr	₹254 Cr	₹160 Cr	₹187 Cr	₹148 Cr	₹198 Cr	₹148 Cr	₹156 Cr	₹136 Cr	₹158 Cr	₹143 Cr	₹133 Cr	₹130 Cr
₹95 Cr	₹134 Cr	₹109 Cr	₹102 Cr	₹75 Cr	₹200 Cr	₹113 Cr	₹147 Cr	₹92 Cr	₹145 Cr	₹114 Cr	₹127 Cr	₹79 Cr	₹141 Cr	₹121 Cr	₹44 Cr	₹72 Cr
₹4 L	₹8 L	₹8 L	₹6 L	₹6 L	₹10 L	₹10 L	₹10 L	₹24 L	₹46 L	₹50 L	₹84 L	₹75 L	₹1 Cr	₹91 L	₹1 Cr	₹1 Cr
₹77 Cr	₹114 Cr	₹87 Cr	₹83 Cr	₹57 Cr	₹185 Cr	₹99 Cr	₹133 Cr	₹78 Cr	₹131 Cr	₹100 Cr	₹113 Cr	₹65 Cr	₹126 Cr	₹106 Cr	₹30 Cr	₹58 Cr
₹56 Cr	₹89 Cr	₹64 Cr	₹61 Cr	₹43 Cr	₹142 Cr	₹74 Cr	₹99 Cr	₹58 Cr	₹97 Cr	₹75 Cr	₹84 Cr	₹48 Cr	₹94 Cr	₹79 Cr	₹22 Cr	₹43 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
—	—	—	—	—	—	—
₹10 Cr	₹10 Cr	₹10 Cr	₹10 Cr	₹10 Cr	₹10 Cr	₹10 Cr
₹2007 Cr	₹1802 Cr	₹1516 Cr	₹1280 Cr	₹1094 Cr	₹990 Cr	₹761 Cr
₹2007 Cr	₹1802 Cr	₹1516 Cr	₹1280 Cr	₹1094 Cr	₹990 Cr	₹761 Cr
₹2017 Cr	₹1813 Cr	₹1527 Cr	₹1290 Cr	₹1103 Cr	₹999 Cr	₹770 Cr
-₹2 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹0	₹0	₹0	₹6 Cr	₹31 Cr	₹56 Cr	₹36 Cr
₹42 Cr	₹34 Cr	₹28 Cr	₹23 Cr	₹21 Cr	₹17 Cr	₹15 Cr
₹1 Cr	₹63 L	₹2 Cr	₹16 L	₹31 L	₹2 Cr	₹3 Cr
₹4 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr
₹48 Cr	₹37 Cr	₹32 Cr	₹32 Cr	₹54 Cr	₹77 Cr	₹55 Cr
—	—	—	—	—	—	—
₹102 Cr	₹113 Cr	₹94 Cr	₹94 Cr	₹83 Cr	₹46 Cr	₹71 Cr
₹56 Cr	₹55 Cr	₹38 Cr	₹62 Cr	₹66 Cr	₹54 Cr	₹42 Cr
₹0	₹38 L	₹0	₹0	₹4 Cr	₹5 Cr	₹0
₹11 Cr	₹16 Cr	₹9 Cr	₹36 Cr	₹191 Cr	₹131 Cr	₹110 Cr
₹169 Cr	₹184 Cr	₹142 Cr	₹192 Cr	₹344 Cr	₹236 Cr	₹223 Cr
₹2232 Cr	₹2034 Cr	₹1701 Cr	₹1514 Cr	₹1502 Cr	₹1313 Cr	₹1049 Cr
₹4 Cr	₹4 Cr	₹14 Cr	₹14 Cr	₹13 Cr	₹4 Cr	₹4 Cr
₹0	₹38 L	₹6 Cr	₹31 Cr	₹61 Cr	₹86 Cr	₹48 Cr
—	—	—	—	—	—	—
₹1163 Cr	₹1097 Cr	₹828 Cr	₹793 Cr	₹720 Cr	₹645 Cr	₹311 Cr
₹374 Cr	₹302 Cr	₹253 Cr	₹200 Cr	₹147 Cr	₹99 Cr	₹72 Cr
₹789 Cr	₹795 Cr	₹575 Cr	₹593 Cr	₹573 Cr	₹546 Cr	₹240 Cr
₹78 Cr	₹50 Cr	₹211 Cr	₹173 Cr	₹74 Cr	₹18 Cr	₹141 Cr
₹89 Cr	₹19 Cr	₹2 Cr	₹12 L	₹26 L	₹37 L	₹81 L
₹89 Cr	₹19 Cr	₹2 Cr	₹12 L	₹26 L	₹37 L	₹81 L
₹18 Cr	₹12 Cr	₹13 Cr	₹12 Cr	₹221 Cr	₹141 Cr	₹128 Cr
₹7 Cr	₹23 Cr	₹3 Cr	₹9 Cr	₹82 L	₹45 L	₹67 L
₹982 Cr	₹899 Cr	₹804 Cr	₹786 Cr	₹869 Cr	₹706 Cr	₹510 Cr
—	—	—	—	—	—	—
₹402 Cr	₹317 Cr	₹244 Cr	₹137 Cr	₹73 Cr	₹141 Cr	₹198 Cr
₹326 Cr	₹240 Cr	₹208 Cr	₹212 Cr	₹195 Cr	₹154 Cr	₹111 Cr
₹460 Cr	₹522 Cr	₹350 Cr	₹274 Cr	₹232 Cr	₹178 Cr	₹184 Cr
₹14 Cr	₹1 Cr	₹47 Cr	₹43 Cr	₹89 Cr	₹61 Cr	₹3 Cr
₹18 Cr	₹29 Cr	₹27 Cr	₹46 Cr	₹33 Cr	₹40 Cr	₹14 Cr
₹30 Cr	₹27 Cr	₹21 Cr	₹16 Cr	₹10 Cr	₹34 Cr	₹29 Cr
₹1250 Cr	₹1135 Cr	₹896 Cr	₹728 Cr	₹633 Cr	₹607 Cr	₹539 Cr
₹1081 Cr	₹951 Cr	₹754 Cr	₹536 Cr	₹288 Cr	₹371 Cr	₹315 Cr
₹2232 Cr	₹2034 Cr	₹1701 Cr	₹1514 Cr	₹1502 Cr	₹1313 Cr	₹1049 Cr
₹193	₹173	₹146	₹123	₹1,160	₹1,051	₹810
₹193	₹173	₹146	₹123	₹105	₹96	₹74

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
₹345 Cr	₹495 Cr	₹413 Cr	₹322 Cr	₹238 Cr	₹313 Cr	₹213 Cr
₹37 Cr	₹30 Cr	₹37 Cr	₹47 Cr	₹53 Cr	₹18 Cr	₹12 Cr
-₹14 Cr	-₹171 Cr	-₹81 Cr	-₹52 Cr	-₹22 Cr	-₹89 Cr	-₹22 Cr
₹367 Cr	₹354 Cr	₹369 Cr	₹316 Cr	₹268 Cr	₹242 Cr	₹204 Cr
₹267 Cr	₹245 Cr	₹265 Cr	₹246 Cr	₹207 Cr	₹167 Cr	₹155 Cr
-₹143 Cr	-₹160 Cr	-₹155 Cr	-₹158 Cr	-₹112 Cr	-₹195 Cr	-₹113 Cr
-₹113 Cr	-₹99 Cr	-₹99 Cr	-₹85 Cr	-₹100 Cr	₹31 Cr	-₹43 Cr
₹11 Cr	-₹14 Cr	₹12 Cr	₹3 Cr	-₹4 Cr	₹3 Cr	-₹1 Cr
₹90 L	₹15 Cr	₹3 Cr	₹67 L	₹5 Cr	₹2 Cr	₹4 Cr
₹12 Cr	₹90 L	₹15 Cr	₹3 Cr	₹67 L	₹5 Cr	₹2 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Concord Biotech Share Price

1480.00-80.30 (-5.15%)

-8.89% past 1 Year

Shareholding summary

Promoters

44.08%

FII

7.53%

DII

4.97%

4.4%

Others

39.02%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
44.08%	44.08%	44.08%	44.08%	44.08%	44.08%
7.53%	7.79%	7.58%	8.03%	9.10%	9.35%
4.97%	4.92%	5.13%	5.01%	4.16%	3.99%
4.40%	4.30%	4.44%	4.53%	4.68%	5.16%
39.02%	38.91%	38.77%	38.35%	37.98%	37.42%

Bulk & block deals

Name

Dsp Mutual Fund

1575773 Ontario Inc

Nk Securities Research Private Limited

The Vanguard Group Inc A/C Vanguard Total International Stock Index Fund

The Vanguard Group Inc A/C Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard Internat

Ubs Principal Capital Asia Limited

Norges Bank On Account Of The Government Pension Fund Global

1575773 Ontario Inc

Societe Generale

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
31 Aug 2026	Purchase	180.86 Cr	₹1,404.10	12.88 L	Bulk	1.231276	BSE
31 Aug 2026	Sell	293.78 Cr	₹1,404.10	20.92 L	Bulk	2.000001	BSE
25 Feb 2026	Purchase	75.14 Cr	₹1,217.94	6.17 L	Bulk	0.589729	NSE
25 Feb 2026	Sell	75.18 Cr	₹1,218.58	6.17 L	Bulk	0.589729	NSE
20 Sep 2024	Purchase	181.19 Cr	₹2,596.08	6.98 L	Bulk	0.66714	NSE
20 Sep 2024	Purchase	149.84 Cr	₹2,596.08	5.77 L	Bulk	0.551715	NSE
20 Sep 2024	Sell	191.69 Cr	₹2,589.86	7.40 L	Bulk	0.707499	NSE
28 May 2024	Purchase	83.22 Cr	₹1,386.95	6 L	Bulk	0.573525	NSE
28 May 2024	Sell	483 Cr	₹1,361.26	35.48 L	Bulk	3.391646	NSE
25 Jan 2024	Purchase	21.81 Cr	₹1,421.70	1.53 L	Block	0.146651	BSE

Insider trading & SAST

Client name

Prakash Lalchand Sajnani

Chandrashekhar Mukundrao Chawan

Devang Bhatt

Kanishka Kapoor

Ravi Kapoor

1575773 Ontario Inc

Raksha Modi

Rajendra Modi

Raksha Modi

Mr. Chandrashekhar Mukundrao Chawan

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
23 Sep 2024	Designated Person	Disposal	0.004779	0.02	1.08 Cr	₹2,168.80	5 K	16 Sep 2024 - 22 Sep 2024	Market Sale	17,000	Insider Trading	—	Equity Shares
23 Sep 2024	Designated Person	Disposal	0.000956	0.01	21.09 L	₹2,109.40	1 K	16 Sep 2024 - 22 Sep 2024	Market Sale	9,039	Insider Trading	—	Equity Shares
04 Sep 2024	Designated Person	Disposal	0.002868	0.01	52.04 L	₹1,734.79	3 K	02 Sep 2024	Market Sale	8,056	Insider Trading	—	Equity Shares
13 Jun 2024	Directors Immediate Relative	Disposal	0.009559	0	0	—	10 K	12 Jun 2024	Market Sale	0	Insider Trading	—	Equity Shares
05 Jun 2024	Director	Disposal	0.009559	0.2	0	—	10 K	04 Jun 2024	Gift	2,10,000	Insider Trading	—	Equity Shares
03 Jun 2024	Other	Disposal	3.39	2	0	—	35.48 L	28 May 2024	Market	20,92,325	SAST	29(2)	—
27 Feb 2024	Employees Immediate Relative	Disposal	0.001912	0.02	29.85 L	₹1,492.37	2 K	26 Feb 2024	Market Sale	18,000	Insider Trading	—	Equity Shares
27 Feb 2024	Designated Person	Disposal	0.003823	0.02	59.98 L	₹1,499.52	4 K	26 Feb 2024	Market Sale	18,000	Insider Trading	—	Equity Shares
24 Feb 2024	Employees Immediate Relative	Disposal	0.001912	0.02	29.33 L	₹1,466.52	2 K	23 Feb 2024	Market Sale	20,000	Insider Trading	—	Equity Shares
24 Feb 2024	Designated Person	Disposal	0.000956	0.01	14.45 L	₹1,444.90	1 K	23 Feb 2024	Market Sale	10,039	Insider Trading	—	Equity Shares

Concord Biotech Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Concord Biotech Share Price

Concord Biotech Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Concord Biotech Share Price

Concord Biotech Share Price

Oscillators

Moving averages

Concord Biotech Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Concord Biotech Share Price

Corporate Actions

Company details

Concord Biotech Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Concord Biotech Share Price

News

Concord Biotech Approves One To One Bonus Issue And Raises Capital

Concord Biotech Q1 EBITDA rises sharply with improved margin performance

Concord Biotech posts strong Q1 revenue growth on robust year-on-year performance

Concord Biotech reports higher Q1 net profit on steady quarterly earnings

Concord Biotech schedules Q1 FY2026 earnings conference call for investors

Concord Biotech clears Kenya, Uganda inspections at Unit-II formulation plant

Brazilian Health Regulatory Agency completes inspection at Concord Biotech’s API manufacturing facility in Limbasi

Concord Biotech completes Anvisa inspection at Limbasi API site

Concord Biotech zooms after getting USFDA’s nod for Tofacitinib Tablets

Concord Biotech gets USFDA’s nod for Tofacitinib Tablets

Concord Biotech gains USFDA nod for Tofacitinib tablets with US sales potential

Concord Biotech soars on getting USFDA nod for Mycophenolate Mofetil for Oral Suspension

Concord Biotech gets USFDA nod for Mycophenolate Mofetil oral suspension

Kotak maintains Add rating on Concord Biotech with strong FY27–29 growth view

Jefferies keeps Hold rating on Concord Biotech after weak Q4 print

Concord Biotech informs about press release

Concord Biotech upbeat on FY27 growth outlook from products, customers mix shift

Concord Biotech - Quaterly Results

Concord Biotech Q4 EBITDA declines sharply with margin compression YoY

Concord Biotech reports lower Q4 profit and revenue year on year

Concord Biotech Ltd Share Price Today

Concord Biotech Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator